Samsung Epis (0126Z0) Stock Price, Fundamentals & Analysis

What 0126Z0 does

Samsung Epis (0126Z0) is a stock listed on the Korea Exchange in the Healthcare sector, specifically in the Biotechnology industry. The company, Samsung Epis Holdings Co., Ltd., manages a portfolio of biopharmaceutical products. Founded in 2025 and headquartered in Incheon, South Korea, it operates with a small team of 9 employees. It is part of the broader Korean biotech ecosystem alongside peers such as Celltrion (068270), Chong Kun Dang (185750), and Samsung Biologics (207940).

Key numbers explained

• Price: 330,000 KRW — the current trading price per share.
• Market cap: 8.21T KRW — the total market value of all outstanding shares, calculated as share price multiplied by the number of shares.
• Forward P/E ratio: 24.4 — the price divided by expected future earnings, used to assess how the market values growth.
• Revenue (TTM): 1.51T KRW — the total revenue over the trailing 12 months, showing the scale of business activity.
• Profit margin: 33.9% — the percentage of revenue that remains as profit after all expenses.
• Operating margin: 15% — the percentage of revenue left after covering operating costs, before interest and taxes.
• Debt-to-equity ratio: 7.9% — a measure of financial leverage, showing debt as a percentage of shareholder equity.
• 52-week range: 325,500 – 773,000 KRW — the lowest and highest prices over the past year, indicating the stock's recent volatility.

What to watch

Investors tracking Samsung Epis (0126Z0) may monitor the upcoming earnings report on Oct 23, 2026, which can drive price movement. The stock's performance within the KOSPI 200 index and its relationship to other Korean healthcare names like Green Cross (006280) and SK Bioscience (302440) provide context for sector trends. The relatively low debt-to-equity ratio of 7.9% suggests a conservative capital structure, while the -1.6% price change over the last 52 weeks reflects the stock's recent one-year trajectory.